Modern strategies and capabilities for activation of the immune response against tumor cells

Sennikov, Sergey; Khantakova, Julia N.; Kulikova, E. V.; Obleukhova, I. A.; Shevchenko, Yu.A.

doi:10.1177/1010428317698380

Cited by 5 publications

(5 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumors often occur in immunosuppressed individuals with declined DC functions 25 . Cellular immune response efficiency depends on Ag capture, processing, delivery to lymph nodes, and presentation to effector cells of the adaptive immune system.…”

Section: Discussionmentioning

confidence: 99%

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Wang

Yu²,

Zheng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Thymosin alpha 1 (Tα1) is a biological response modifier that has been introduced into markets for treating several diseases. Given the short serum half-life of Tα1 and the rapid development of Fc fusion proteins, we used genetic engineering method to construct the recombinant plasmid to express Tα1-Fc (Fc domain of human IgG4) fusion protein. A single-factor experiment was performed with different inducers of varying concentrations for different times to get the optimal condition of induced expression. Pure proteins higher than 90.3% were obtained by using 5 mM lactose for 4 h with a final production about 160.4 mg/L. The in vivo serum half-life of Tα1-Fc is 25 h, almost 13 times longer than Tα1 in mice models. Also, the long-acting protein has a stronger activity in repairing immune injury through increasing number of lymphocytes. Tα1-Fc displayed a more effective antitumor activity in the 4T1 and B16F10 tumor xenograft models by upregulating CD86 expression, secreting IFN-γ and IL-2, and increasing the number of tumor-infiltrating CD4+ T and CD8+ T cells. Our study on the novel modified Tα1 with the Fc segment provides valuable information for the development of new immunotherapy in cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Wang

Yu²,

Zheng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…К настоящему времени наибольшее распространение получила терапия опухолевых заболеваний дендритными клетками [40]. Эти же клетки, на наш взгляд, представляют интерес для терапии аутоиммунных заболеваний, так как с их помощью можно индуцировать толерантность к тем аутоантигенам, которые являются индукторами развития аутоиммунной патологии в результате «полома» механизмов толерантности [41].…”

Section: к вопросу об иммунотерапии заболеваний с базисным иммунопатоunclassified

Immune paradigm and immunosuppressive dominance in the pathogenesis of major diseases of the modern man

Козлов

2019

Bûll. sib. med.

View full text Add to dashboard Cite

The article discusses the determining role of immunopathogenesis of the main diseases of the modern man (cancer, atherosclerosis, autoimmune, allergic and infectious diseases). In this regard, the concept of «immune paradigm» is introduced. There is evidence that any pathology is based on the classical immune response to the antigen, whether auto- or xenoantigen, with all stages of its development and parallel changes in the state of immune tolerance: its breakdown in cases of autoimmune and allergic diseases and atherosclerosis; its establishment in cases of cancer and infectious diseases. In the meantime, it is emphasized that the immunopathogenesis is based on insufficient or increased function of immunocompetent regulatory cells with suppressive activity. Here the concept of «immunosuppressive dominant» is introduced. Finally, we discuss the need for fundamental changes in treatment of these diseases, with a focus on molecular and cellular immunotherapy methods and development of integrated approaches to their application.

show abstract

“…Tα1, as an immunomodulator used in cancer therapy [1] , has abilities to induce the activation of DCs and T cells as well as the secretion of interferon-gamma (IFN-γ) and interleukin-2 (IL-2) [2] . IFN-γ is important in the immune system stems for its immunomodulatory activity, whereas IL-2 can promote the differentiation of T cells into effector T cells and boost the host immunity against cancer [3] , [4] . Thus, the standard curve data of IFN-γ and IL-2 in melanoma model, and the absorbance of samples treated with Tα1-iRGD were determined and can be found in different sheets.…”

Section: Datamentioning

confidence: 99%

Effects on tumor growth and immunosuppression of a modified Tα1 peptide along with its circular dichroism spectroscopy data

Wang

et al. 2018

Data in Brief

View full text Add to dashboard Cite

The data presented in this article are related to the research article entitled “Immunomodulatory and Enhanced Antitumor Activity of a Modified Thymosin α1 in Melanoma and Lung Cancer” (Wang et al., 2018). Tα1 has been evaluated as effective in cancer treatment. In order to make it capable to target tumor, a peptide iRGD was introduced to Tα1. The anti-tumor activity was accessed by constructing in vivo melanoma and human non-small-cell lung cancer models treated with Tα1-iRGD to measure the tumor volume over time and tumor weight at the last day. The concentration of IFN-γ and IL-2 in C57BL/6 mice peripheral blood was determined by ELISA. And the immunomodulatory ability of Tα1-iRGD was evaluated in vivo by thymus index and spleen index. Those functions this paper was aimed at may have relationship with its secondary structure, so the circular dichroism spectra of Tα1, iRGD and Tα1-iRGD was performed.

show abstract

Modern strategies and capabilities for activation of the immune response against tumor cells

Cited by 5 publications

References 69 publications

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Immune paradigm and immunosuppressive dominance in the pathogenesis of major diseases of the modern man

Effects on tumor growth and immunosuppression of a modified Tα1 peptide along with its circular dichroism spectroscopy data

Contact Info

Product

Resources

About